p38 mitogen-activated protein kinase inhibitors for the treatment of chronic cardiovascular disease.
p38 Mitogen-activated protein kinase (MAPK) has been implicated in cardiovascular disease and is activated by various factors, including neurohormones (e.g., catecholamines, angiotensin II and endothelin), hypoxia and wall stress. Activation of p38 MAPK can cause cardiac hypertrophy, negative inotropy and endothelial dysfunction. All of these conditions lead to chronic cardiovascular disease, which is becoming an ever growing burden on society. p38 MAPK inhibition may therefore be an interesting therapeutic approach to the treatment of various cardiovascular diseases. However, in vitro and in vivo results are conflicting and caution must be applied in the translation of bench results to the clinic.
Behr
Thomas M
TM
Medizinische Poliklinik, Department of Cardiology, University of Wuerzburg, Klinikstrasse 6-8, 97070 Wuerzburg, Germany. Behr_T@medizin.uni-wuerzburg.de
Berova
Marinela
M
Doe
Christopher P
CP
Ju
Haisong
H
Angermann
Christiane E
CE
Boehm
Jeffrey
J
Willette
Robert N
RN
D000818:Animals; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000201:enzymology; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D004791:Enzyme Inhibitors / Q000737:chemistry / Q000627:therapeutic use*; D006321:Heart / Q000187:drug effects; D006801:Humans; D020928:Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors*; D015394:Molecular Structure; D009206:Myocardium / Q000201:enzymology; D048051:p38 Mitogen-Activated Protein Kinases
D004791:Enzyme Inhibitors; D020928:Mitogen-Activated Protein Kinases; D048051:p38 Mitogen-Activated Protein Kinases